Bryan Kay

12 POSTS 0 COMMENTS

Getinge and Cook Medical enter US commercial distribution agreement for iCast...

Getinge and Cook Medical today announced an exclusive sales and distribution agreement for the iCast covered stent system, which recently received US Food and...

‘Get a Pulse on PAD’: Multi-society public awareness campaign launched

The multi-society PAD Pulse Alliance is taking part in a peripheral arterial disease (PAD) public awareness campaign called “Get a Pulse on PAD”. The group—formed...

PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI...

Enrolment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialisation system designed to prevent amputations in so-called "no-option"...

AVF 2022: Six-month CLOUT data indicate ClotTriever can effectively remove full...

Six-month outcomes from the ongoing CLOUT registry demonstrate the “safety and efficacy” of the ClotTriever thrombectomy system (Inari Medical) in a real-world deep vein...

AVF 2022: Emerging autogenous venous valve formation system sees “continual improvement”

An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual...

VEITH 2021: Two-year follow-up data from EVAS2 IDE study delivered

The confirmatory EVAS2 clinical study to evaluate the safety and effectiveness of Endologix's Nellix endovascular aneurysm sealing system (EVAS) for the treatment of infrarenal...

EMINENT one-year results show “superior” primary patency rate for Eluvia DES...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...

VIVA 2021: Consensus established for appropriate use of IVUS in peripheral...

A worldwide committee of 40 cross-speciality medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease...

IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...

Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...

VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...

An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...

Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy

Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...

VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...